Filing Flows › Evolent Health (EVH) › Q2 2026 › vs Q2 2025
Evolent Health (EVH) Q2 2026 vs Q2 2025 (year over year)
Evolent Health's revenue rose $208M (+47%) from $444M in Q2 2025 to $653M in Q2 2026.
Evolent Health, Q2 2026: revenue $653M (+47% year over year), operating margin -1.5%, net loss $28.4M, operating cash flow −$9.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $653M | $444M | $208M | +47% |
| Net loss | $28.4M | $19.9M | $8.5M | +43% |
| Costs & expenses | $681M | $465M | $216M | +46% |
| Operating costs | $662M | $445M | $217M | +49% |
| Interest & other, net | $16.1M | $19.6M | −$3.5M | -18% |
| Income tax | $2.7M | −$825K | $3.5M | — |
| Cost of revenue | $572M | $344M | $228M | +66% |
| SG&A | $68.8M | $75.2M | −$6.4M | -8% |
| Other operating costs | $21.6M | $26.3M | −$4.8M | -18% |
| Operating cash sources | $46.1M | $65.1M | −$19.0M | -29% |
| Depreciation & amortization | $21.6M | $23.1M | −$1.6M | -7% |
| Share-based compensation | $15.2M | $11.6M | $3.6M | +31% |
| Cash used in operations | $9.3M | $30.3M | −$21.0M | -69% |
| Net loss absorbed | $28.4M | $19.9M | $8.5M | +43% |
| Working capital & other | $17.7M | $45.2M | −$27.4M | -61% |
Questions
How much did Evolent Health's revenue grow year over year in Q2 2026?
Evolent Health's revenue rose $208M (+47%) from $444M in Q2 2025 to $653M in Q2 2026.